<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01274754</url>
  </required_header>
  <id_info>
    <org_study_id>VRTE</org_study_id>
    <nct_id>NCT01274754</nct_id>
  </id_info>
  <brief_title>Neuroprotection With Erythromycin in Cardiac Surgery</brief_title>
  <official_title>Perioperative Administration of Erythromycin and Brain Protection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHEPA University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Thessaly</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>AHEPA University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Neurological complications occur in open heart surgery with a frequency of 40% and they range&#xD;
      from major neurological deficits (due to a stroke) to neurocognitive and behavioral&#xD;
      disorders. This study aims to determine if erythromycin, a worldwide known antibiotic,&#xD;
      protects the brain from damage when given in high doses before and during open heart surgery.&#xD;
&#xD;
      The investigators consume that high dose of erythromycin will protect the brain with a&#xD;
      pharmacological preconditioning against the global ischemia during the perioperative period&#xD;
      of heart surgery.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First Version: Study Protocol Authors: Thomaidou E., Vretzakis G., Argiriadou E., Stamatiou&#xD;
      G., et al.&#xD;
&#xD;
      Perioperative administration of erythromycin and brain protection&#xD;
&#xD;
      Study Setting: On-pump, planned cardiac surgery. Randomized, double blinded clinical trial of&#xD;
      two parallel groups. Group A: control group. Group B: erythromycin group (dose 25mg/kg&#xD;
      intravenously).&#xD;
&#xD;
      Purpose:&#xD;
&#xD;
      Neurological complications occur in open heart surgery with a frequency of 40% and they range&#xD;
      from major neurological deficits (due to a stroke) to neurocognitive and behavioral&#xD;
      disorders. This study aims to determine if erythromycin, a worldwide known antibiotic,&#xD;
      protects the brain from damage when given in high doses before and during open heart surgery.&#xD;
&#xD;
      Hypothesis:&#xD;
&#xD;
      The investigators consume that high dose of erythromycin will protect the brain with a&#xD;
      pharmacological preconditioning against the global ischemia during the perioperative period&#xD;
      of heart surgery.&#xD;
&#xD;
      The aims of this study are:&#xD;
&#xD;
        1. To determine the effect of high-dose perioperative erythromycin administration on&#xD;
           neurological outcome in patients undergoing cardiac surgery&#xD;
&#xD;
        2. To determine the relationship of neurological monitoring, specifically NIRS, to&#xD;
           neurological outcomes and to determine if erythromycin affects this relationship.&#xD;
&#xD;
      Preoperative Period&#xD;
&#xD;
      Patient Exclusion Criteria: patients &gt; 80 years old, cerebrovascular disease with residual&#xD;
      deficits, stroke, alcoholism, psychiatric disease.&#xD;
&#xD;
      Preoperative patient neurocognitive status assessment from the same clinical psychologist in&#xD;
      all patients:&#xD;
&#xD;
      at least one day before surgery, perform neurocognitive tests.&#xD;
&#xD;
      Patients of group A: 25mg/kg erythromycin intravenously 12 hours before surgery.&#xD;
&#xD;
      Intraoperative Period&#xD;
&#xD;
      Cerebral monitoring: continuous measurement and registration of cerebral oximetry data (NIRS&#xD;
      - INVOS), record of frequency and duration of desaturation episodes (a fall &gt;20% compared to&#xD;
      baseline values) and record of interventions to correct desaturation.&#xD;
&#xD;
      Anaesthesia depth monitoring: continuous measurement of bispectral index (BIS).&#xD;
&#xD;
      Registration of: duration of CPB and cross clamp time, mean arterial pressure, heart rate,&#xD;
      temperature and ETCO2.&#xD;
&#xD;
      Anesthesia Procedures: anesthesia induction with fentanyl 10-15Î¼g/kg, propofol 2gm/kg and&#xD;
      rocuronium 0,6mg/kg. Anesthesia maintenance with propofol.&#xD;
&#xD;
      Postoperative Period - ICU&#xD;
&#xD;
      Postoperative patient neurocognitive status assessment from the same clinical psychologist in&#xD;
      all patients:&#xD;
&#xD;
      On discharge, and 3 months later perform neurocognitive tests.&#xD;
&#xD;
      Patients of group A: will receive high dose of erythromycin 12 hours after the end of&#xD;
      surgery.&#xD;
&#xD;
      Registration of:&#xD;
&#xD;
      Post operative blood loss, duration of ICU stay, mechanical ventilation duration, duration of&#xD;
      hospital stay, inotropic support, postoperative myocardial infarction, re-operation,&#xD;
      dialysis, neurocognitive decline, other complications.&#xD;
&#xD;
      BIOCHEMICAL INDEX&#xD;
&#xD;
      Blood samples will be taken from all patients for the detection of tau protein, IL-1 and&#xD;
      IL-6,&#xD;
&#xD;
        1. preoperatively&#xD;
&#xD;
        2. 12 hours after surgery&#xD;
&#xD;
        3. the 6th day after surgery&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2008</start_date>
  <completion_date type="Actual">September 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>biochemical markers of brain ischemia and intraoperative cerebral oxymetry data</measure>
    <time_frame>September 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>better neurocognitive outcome in Erythromycin group</measure>
    <time_frame>November 2010</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Functional Disturbances Following Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>erythromycin group</arm_group_label>
    <description>Patients of erythromycin group: 25mg/kg erythromycin intravenously 12 hours before surgery and 12 hours after the end of surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <description>no administration of erythromycin</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples will be taken from all patients for the detection of tau protein, IL-1 and&#xD;
      IL-6,&#xD;
&#xD;
        1. preoperatively&#xD;
&#xD;
        2. 12 hours after surgery&#xD;
&#xD;
        3. the 6th day after surgery&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients scheduled for elective cardiac surgey coronary artery bypass grafting&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  patients &lt; 80 years old scheduled for elective cardiac surgery coronary artery bypass&#xD;
             grafting, good cooperation with the clinical psychologist&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients &gt; 80 years old&#xD;
&#xD;
          -  cerebrovascular disease with residual deficits&#xD;
&#xD;
          -  stroke&#xD;
&#xD;
          -  alcoholism&#xD;
&#xD;
          -  psychiatric disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>George Vretzakis, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>University of Thessaly</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ahepa University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <state>Hotmail</state>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ahepa University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <zip>54636</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>January 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2011</study_first_posted>
  <last_update_submitted>December 1, 2014</last_update_submitted>
  <last_update_submitted_qc>December 1, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>AHEPA University Hospital</investigator_affiliation>
    <investigator_full_name>Evanthia Thomaidou</investigator_full_name>
    <investigator_title>Consultant Anesthesiologist</investigator_title>
  </responsible_party>
  <keyword>neuroprotection</keyword>
  <keyword>erythromycin</keyword>
  <keyword>neurocognitive assessment</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

